文燦股份(603348.SH):“文燦轉債”將開始轉股
格隆匯12月9日丨文燦股份(603348.SH)公佈,經中國證券監督管理委員會“證監許可[2019]865號”文核准,公司於2019年6月10日公開發行了800萬張可轉換公司債券,每張面值100元,發行總額8億元,期限6年。
根據有關規定和公司募集説明書的約定,公司該次發行的“文燦轉債”自2019年12月14日起可轉換為本公司股份(如遇法定節假日或休息日延至其後的第1個工作日),即順延至2019年12月16日可開始轉股。
轉股價格為19.93元/股;轉股期起止日期為2019年12月14日至2025年6月9日止(如遇法定節假日或休息日延至其後的第1個工作日),即順延至2019年12月16日可開始轉股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.